This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Mdxhealth, Sa. Active years: 2016-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2018
Title: Ate G J Van Der Zee: Innovator in Cervical Cancer Diagnostics
Introduction
Ate G J Van Der Zee is a notable inventor based in Groningen, Netherlands. He has made significant contributions to the field of cervical cancer diagnostics through his innovative patents. With a total of 2 patents, his work focuses on methods for identifying and monitoring cervical cancer.
Latest Patents
Van Der Zee's latest patents include groundbreaking inventions related to the methylation of the EPB41L3 gene. The first patent describes methods and kits for identifying, diagnosing, prognosing, and monitoring cervical cancer. This invention emphasizes the importance of determining the methylation status or the expression levels of specific genes. The second patent also focuses on the detection and prognosis of cervical cancer, utilizing similar methodologies to enhance diagnostic accuracy.
Career Highlights
Throughout his career, Ate G J Van Der Zee has worked with prominent companies in the healthcare sector, including Mdxhealth. His expertise in cancer diagnostics has positioned him as a key figure in the development of innovative solutions for cervical cancer.
Collaborations
Some of his notable coworkers include Luc Dehaspe and E M D Schuuring, who have collaborated with him on various projects related to cancer research and diagnostics.
Conclusion
Ate G J Van Der Zee's contributions to cervical cancer diagnostics through his patents highlight his commitment to improving healthcare outcomes. His innovative methods continue to pave the way for advancements in cancer detection and monitoring.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile